Tracking cancer treatment effects on pregnant women and their babies
Maternal Cancer Diagnosis and Treatment During Pregnancy:a Registry for Maternal, Fetal, and Neonatal Outcomes With Longitudinal Follow up of Child Development and Maternal Psychological Well Being
This study is tracking pregnant women with cancer to see how their treatments affect both their health and the health of their babies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Sex | Female |
| Sponsor | The Cooper Health System Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Camden, New Jersey) |
| Trial ID | NCT02749474 on ClinicalTrials.gov |
What this trial studies
This observational study aims to follow pregnant women diagnosed with cancer to assess the impact of their treatment options on both their health and the health of their children. It collects data on diagnosis methods, treatment choices, and maternal and neonatal outcomes at delivery, with follow-ups extending into childhood and adulthood. The study recognizes that cancer complicates approximately 1 in 1000 pregnancies, with breast cancer being the most common type diagnosed during this period. The research seeks to provide insights into the safety and outcomes of cancer treatments during pregnancy.
Who should consider this trial
Good fit: Ideal candidates for this study are pregnant women diagnosed with cancer within six weeks before their last menstrual period or within six months after the end of their pregnancy.
Not a fit: Patients diagnosed with cancer more than six months after the end of a pregnancy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve understanding of how cancer treatments during pregnancy affect both mothers and their children, leading to better clinical guidelines.
How similar studies have performed: Previous studies have shown that treatment during pregnancy can be safe and effective, but this specific registry approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any pregnant woman diagnosed with cancer within 6 weeks before her last menstrual period or 6 months after her end of pregnancy either by delivery or miscarriage. Exclusion Criteria: * Women diagnosed with cancer more than 6 months after the end of a pregnancy.
Where this trial is running
Camden, New Jersey
- Cooper University Hospital — Camden, New Jersey, United States (Recruiting)
Study contacts
- Principal investigator: Elyce H Cardonick, MD — Cooper Health System
- Study coordinator: Elyce H Cardonick, MD
- Email: cardonick-elyce@cooperhealth.edu
- Phone: 856342 2065
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.